PAM Theragnostics

Recent Finacing

Series A I

Recent Raise

$1.7M

PAM Theragnostics develops the PAM enzyme as a preventive Alzheimer's drug candidate and operates biomarker diagnostics using circulating PAM measurements for early detection and prediction, advancing preclinical development.